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Cardiovascular disease encompasses a range of conditions extending from myocardial infarction
to congenital heart disease, most of which are heritable. Enormous effort has been invested
in understanding the genes and specific DNA sequence variants that are responsible for this
heritability. Here, we review the lessons learned for monogenic and common, complex forms of
cardiovascular disease. We also discuss key challenges that remain for gene discovery and for
moving from genomic localization to mechanistic insights, with an emphasis on the impact of
next-generation sequencing and the use of pluripotent human cells to understand the mechanism
by which genetic variation contributes to disease.Introduction
Cardiovascular disease (CVD) is a leading health problem,
affecting more than 80,000,000 individuals in the United States
alone. CVD encompasses a broad range of disorders, including
diseases of the vasculature, diseases of the myocardium,
diseases of the heart’s electrical circuit, and congenital
heart disease (Roger et al., 2012). For nearly all of these disor-
ders, inherited DNA sequence variants play a role in conferring
risk for disease. For example, in the general population, a history
of premature atherosclerotic CVD in a parent confers 3.0-fold
increase in CVD risk to offspring (Lloyd-Jones et al., 2004). The
precise magnitude of the role of inheritance, however, varies
by disease and by other factors such as age of disease onset
and subtype of disease.
Over the past century, a key goal of biomedical research
has been to correlate genotype with phenotype, i.e., to identify
the specific genes and DNA sequence variants responsible
for trait variation in humans. What is the principal reason to
pursue this goal? Naturally occurring genetic variation has the
unique potential to reveal causal biologic mechanisms in
humans. This is particularly important, as some diseases like
myocardial infarction (MI) are poorly modeled in nonhuman
species.
In this Review, we consider the approaches used to discover
genes for human CVD and the lessons learned from the study
of Mendelian and of common, complex forms of CVD, and
we take a look forward at research driven by next generation
techniques, including sequencing and modeling human genetic
disease in cells.
Approaches to Discover Genes for CVD
To discover genes for CVD and its risk factors in humans, two
major approaches—linkage analysis and genetic association—
have been utilized. The choice of approach has depended on
the pattern of segregation, whether consistent with the ratios1242 Cell 148, March 16, 2012 ª2012 Elsevier Inc.described by Mendel or more complex. Some forms of CVD
exhibit a simple pattern of inheritance suggestive of a single
causal gene that confers a large effect on phenotype. For
many of these Mendelian forms of CVD, direct DNA sequencing
and/or linkage analysis have successfully yielded the causal
gene and mutation. In 1985, Lehrman and colleagues directly
sequenced the low-density lipoprotein receptor (LDLR) gene in
a patient with homozygous familial hypercholesterolemia and
uncovered a 5 kilobase deletion that eliminated several exons,
representing the first demonstration of a mutation for Mendelian
CVD (Lehrman et al., 1985). In 1989, linkage analysis was
used to localize the chromosomal position of a causal gene for
hypertrophic cardiomyopathy, and in the subsequent year,
mutations in the beta cardiac myosin heavy chain were discov-
ered as causal for the phenotype (Geisterfer-Lowrance et al.,
1990; Jarcho et al., 1989). Other prominent examples in the
CVD field include long QT syndrome, severe hypercholesterol-
emia, a Mendelian family with early coronary artery disease,
Mendelian forms of hypertension, Marfan’s syndrome, and
several forms of congenital heart disease, including septal
defects and valve defects (Abifadel et al., 2003; Basson et al.,
1997; Berge et al., 2000; Curran et al., 1995; Dietz et al., 1991;
Garcia et al., 2001; Garg et al., 2003, 2005; Lifton et al., 2001;
Mani et al., 2007; Schott et al., 1998; Soria et al., 1989; Tartaglia
et al., 2001).
However, most CVD traits, such as MI or concentrations of
plasma LDL cholesterol, show complex inheritance, suggestive
of an interplay between multiple genes and nongenetic factors.
Mapping gene loci associated with complex traits requires
substantial levels of information and analysis, but since
2007, approaches to accomplish this goal have matured, and
genetic mapping for complex traits in humans has become
a reality. The intellectual foundations that enabled a systematic
genome-wide screen of common variants (termed genome-
wide association study [GWAS]) and results from this approach
were recently reviewed (Altshuler et al., 2008; O’Donnell and
Nabel, 2011). The tools and methods included catalogs of
polymorphisms, techniques to genotype these DNA sequence
variants, and the analytical framework to distinguish true
association signal from false positives. The initial focus has
been on utilizing common DNA sequence variants (variants
with allele frequency > 1:20) as a discovery tool, largely
because it was practical to do so; recent advances in DNA
sequencing and genotyping technology will allow interrogation
of less frequent variants and will be considered below. The
National Human Genome Research Institute hosts a catalog
of published GWAS results, and as of January 14, 2012, the
catalog includes 1,143 publications and 5,585 single-nucleotide
polymorphisms (SNPs) with association evidence at p < 105
(Hindorff et al., 2009).
What have we learned from these gene discovery efforts?
Below, we discuss lessons that have emerged from geno-
type-to-phenotype correlation studies for Mendelian diseases,
followed by lessons from studies of common, complex
diseases.
Lessons Learned from the Study of Mendelian
Forms of CVD
Rare Variants Lead to Broadly Relevant Insights
Because Mendelian diseases are rare in the population, there
was initial skepticism about whether the genes and mechanisms
that cause these diseases would inform our understanding
of common forms of CVD. Linkage studies involve identifying
and recruiting families with unique, often severe phenotypes,
isolating a chromosomal segment that tracks with disease
status in the family, and then pinpointing the causal gene and
mutation in the linked segment. For a range of conditions, the
genes identified by these linkage studies have transformed
our understanding of CVD. Selected examples of Mendelian
diseases, the responsible genes, and the gleaned biological
and clinical insights are detailed in Table 1. Of particular
significance is monogenic severe hypercholesterolemia, for
which the six responsible genes have led to fundamental new
biological concepts and have supported the development of
new therapies.
Genotype-Phenotype Correlation Can Be Complex
Even in Monogenic Disorders
Although there are cases in which single gene mutations lead to
straightforward genotype-phenotype associations, other more
complex relationships exist as well. This complexity can arise
from three distinct genetic phenomena: pleiotropy, penetrance,
and expressivity. Sometimes, mutations in a single gene can
influence multiple phenotypic traits (i.e., pleiotropy). In 1995,
Wang, Keating, and colleagues identified the a subunit of the
type V voltage-gated sodium channel (SCN5A) as the cause of
inherited long QT syndrome type 3 (Wang et al., 1995). Since
then, mutations in the same gene have been demonstrated to
cause Brugada syndrome (right precordial ST-segment eleva-
tion and increased risk for ventricular arrhythmias), cardiac
conduction system disease, and dilated cardiomyopathy (Chen
et al., 1998; McNair et al., 2004; Schott et al., 1999). This range
of disease phenotypes may reflect the underlying functionality
of the channel.Among carriers of a Mendelian mutation in a given family,
some may exhibit the condition and others may not. Penetrance
refers to the proportion of individuals with a given genotype
who exhibit the phenotype associated with the genotype. In
many Mendelian cardiovascular conditions inherited in an
autosomal-dominant manner, there is evidence for incomplete
penetrance. For example, Hobbs and colleagues reported that,
in a pedigree with familial hypercholesterolemia due to a point
mutation in LDLR, only 12 out of 18 heterozygotes had high
LDL cholesterol (>95th percentile), whereas some of the remain-
ing 6 had LDL cholesterol as low as 28th percentile for the
population (Hobbs et al., 1989). The lack of a high-cholesterol
phenotype given the same genotype may be due to modifier
genes or environmental influences.
Individuals with the same Mendelian genotype can also show
different degrees of the same phenotype. Expressivity is the
degree to which trait expression differs among individuals.
Marfan’s syndrome is a multisystem Mendelian disorder that
can include a range of signs and symptoms involving the skeletal
system (pectus excavatum, increased arm span to height ratio,
craniofacial alterations), ocular system (eye lens dislocation, flat
cornea), and cardiovascular system (aortic aneurysm, dissection
of the ascending aorta, mitral valve prolapse), among others
(Can˜adas et al., 2010). Dietz and colleagues identified mutations
in the FBN1 gene encoding the extracellularmatrix protein fibrillin
1 as responsible forMarfan’s syndrome (Dietz et al., 1991).When
a specific mutation in the fibrillin 1 (FBN1) gene causes Marfan’s
syndrome in a family, carriers of the same mutation can display
variable clinical manifestations (Faivre et al., 2007).
Pleiotropy, penetrance, expressivity, and nongenetic factors
conspire to ensure that, even in a single gene disorder, genotype
does not ‘‘equal’’ a specific phenotype. This complexity has
several consequences. First, gene discovery is more difficult,
as genotype may not segregate perfectly with phenotype,
thereby reducing the power of linkage. Second, there is intense
interest in identifying modifiers—genetic or environmental—that
may modulate the relationship between genotype and pheno-
type. Finally, because of this complexity, in many Mendelian
diseases, it has been difficult to develop genotype-specific
prognostic or treatment recommendations.
The Long Road from Genotype to Mechanism
to Treatment
For Marfan’s syndrome, the path from the discovery of FBN1
as the causal gene to a breakthrough in the molecular under-
standing of the disease has spanned more than two decades.
Historically, Marfan’s syndrome had been viewed as a structural
disease due to a defect in elastic fibers (Lindsay andDietz, 2011).
The identification of mutations in an extracellular matrix protein
seemed to confirm this view. However, more recent studies
suggest that microfibrils normally bind the large latent complex
of the cytokine transforming growth factor b (TGF-b) and that
failure of this event to occur results in increased TGF-b activation
and signaling. Now, investigators are exploring the hypothesis
that blocking TGF-b signaling will ameliorate the growth of
aortic aneurysms in Marfan’s syndrome. For further examples
of therapeutic approaches derived from the study of Mendelian
disorders, we refer the reader to a recent review on this topic
(Dietz, 2010).Cell 148, March 16, 2012 ª2012 Elsevier Inc. 1243
Table 1. Selected Examples of Mendelian Diseases and Insights Derived from the Study of Causal Genes
Mendelian Condition Causal Genes Key Biological and Clinical Insights References
Severe
hypercholesterolemia
LDLR, APOB, ABCG5,
ABCG8, ARH, PCSK9
(1) Receptor-mediated endocytosis;
(2) receptor recycling; (3) feedback
regulation of receptors; (4) molecular
mechanism of intestinal cholesterol
absorption and biliary cholesterol
excretion; (5) high LDL cholesterol is
sufficient to cause MI.
(Abifadel et al., 2003;
Brown and Goldstein, 1986;
Garcia et al., 2001;
Lehrman et al., 1985)
Familial
hypobetalipoproteinemia
APOB, PCSK9, ANGPTL3 (1) Lifelong low-LDL cholesterol
(from loss-of-PCSK9 function) is
sufficient to protect from MI despite
other coronary risk factors.
(Cohen et al., 2006;
Musunuru et al., 2010a;
Soria et al., 1989)
Mendelian forms of low
and high blood pressure
SLC12A3, SLC12A1, KCNJ1,
CLCNKB, NR3C2, SCNN1A,
SCNN1B, SCNN1G;
CYP11B2, CYP11B1,
HSD11B2, NR3C2,
SCNN1B, SCNN1G, WNK1,
WNK4, KLHL3, CUL3
(1) Genes converge on a final common
pathway of altering net renal sodium
handling and balance; (2) identification
of new targets for the treatment
of blood pressure.
(Boyden et al., 2012;
Chang et al., 1996; Geller et al.,
2000; Geller et al., 1998;
Hansson et al., 1995; Lifton
et al., 1992a, 1992b, 2001; Mune
et al., 1995; Shimkets et al., 1994;
Simon et al., 1996a, 1996b, 1996c,
1997; Wilson et al., 2001)
Hypertrophic
cardiomyopathy
MYH7, TNNT2, TPM1,
TNNI3, MYL2, MYBPC3,
ACTC, MYL3
(1) Mutations have expanded knowledge
of the molecular mechanisms of heart
muscle contraction; (2) mutations may
cause increased TGF-b signaling in the
myocyte with subsequent effects on
neighboring fibroblasts, leading to
fibrosis and scarring.
(Bonne et al., 1995; Carrier et al.,
1993; Geisterfer-Lowrance et al.,
1990; Kimura et al., 1997;
Olson et al., 2000; Poetter et al.,
1996; Seidman and Seidman, 2001;
Thierfelder et al., 1994;
Watkins et al., 1995)
Marfan’s syndrome FBN1 (1) Aneurysm formation is likely due to
perturbations in cytokine signaling
cascades and the smooth muscle
contractile apparatus rather than defects
in the extracellular matrix; (2) unexpected
role for TGF-b pathway in disease.
(Dietz et al., 1991;
Lindsay and Dietz, 2011)
Atrial or ventricular
septal defects
NKX2-5, GATA-4, TBX5 (1) These transcription factors, originally
discovered in flies and mice, are critical
for proper heart development in humans
and function in a common complex.
(Basson et al., 1997; Garg et al.,
2003; Schott et al., 1998)
Bicuspid aortic
valve, Calcific
aortic valve disease
NOTCH1 (1) NOTCH1 functions to repress a default
osteoblast fate of the valve mesenchymal
cells; (2) NOTCH1 mutations likely result
in a derepression of this fate choice and
subsequent differentiation of valve cells
into an osteoblast-like phenotype.
(Garg et al., 2005)Lessons Learned from the Study of Common, Complex
Forms of CVD
Gene Variants across the Spectrum of Allele Frequency
Contribute to Most Complex, Common Diseases and
Quantitative Traits
Variants associated with common, complex traits range in
frequency from common (>1:20 frequency) to low-frequency
(1:1,000 to 1:20) to very rare (<1:1,000). In other words, genetic
heterogeneity from variants across the frequency spectrum
may be the rule. Consider the example of plasma triglycerides,
a phenotype that marks triglyceride-rich lipoproteins, including
very low-density lipoprotein particles, chylomicrons, and
remnant products of their metabolism. Roughly 50% of the inter-
individual variability in plasma triglycerides is estimated to be1244 Cell 148, March 16, 2012 ª2012 Elsevier Inc.on the basis of DNA sequence variants. Johansen, Hegele, and
colleagues studied individuals from the extremes of the plasma
triglyceride distribution (438 individuals with high triglycerides
[mean triglycerides = 14.2 mmol/l] and 327 individuals with low
triglycerides [mean triglycerides = 1.2 mmol/l]) (Johansen et al.,
2010) using both GWAS and resequencing of selected genes.
In the GWAS, common variants at seven loci were associated
with plasma triglycerides, and in the resequencing study, there
was an excess of rare, nonsynonymous variants across four
genes in individuals with high triglycerides when compared
with those with low triglycerides. A comprehensive logistic
regression model including clinical variables and both common
and rare genetic variants explained 42% of total variation in
hypertriglyceridemia diagnosis: clinical variables explained
Figure 1. Overlap of Genetic Loci Causing
Mendelian Dyslipidemic Syndromes, Those
Targeted by Lipid-Lowering Therapies, and
Those Identified in GWAS
Each GWAS locus is named according to a plau-
sible biologic candidate in the locus or in the gene
nearest to the lead single-nucleotide poly-
morphism (SNP). Note that, for most GWAS loci,
the causal gene is not yet proven. Of 19 genes
previously implicated in Mendelian lipid disorders,
16 of the genes underlying these Mendelian
disorders lie within 100 kilobases of one of the lead
SNPs mapped by GWAS, including nine that lie
within 10 kilobases of the nearest lead SNP (Te-
slovich et al., 2010).20%, common genetic variants in seven loci explained 21%,
and rare genetic variants in four loci explained 1%. The genetic
architecture for triglycerides in the population appears to be
that of a mosaic comprised of large-effect variants rare in
frequency, small-effect variants common in frequency, and
environmental influences.
More generally, the concept of a mosaic model is supported
by the fact that, for many cardiovascular traits and diseases,
there is strong overlap between the genes mapped using
GWAS and those identified earlier through Mendelian families.
Nineteen genes have been identified as monogenic causes of
extremely low or high levels of LDL cholesterol, high-density lipo-
protein (HDL) cholesterol, and triglycerides; loci harboring 16 of
these geneswere alsomapped usingGWAS (Figure 1) (Teslovich
et al., 2010). Rare mutations in FBN1 cause the thoracic aortic
aneurysms and dissections seen inMarfan’s syndrome, whereas
common SNPs in the introns of FBN1 are the top association
result in a GWAS for spontaneous, nonsyndromic thoracic aortic
aneurysm and dissection (Lemaire et al., 2011). Rare mutations
in SCN5A, KCNQ1, KCNH2, KCNE1, and KCNJ2 cause mono-
genic long QT syndrome, whereas common SNPs in these five
genes are associated with QT interval measured on electrocar-
diograms in the population (Newton-Cheh et al., 2009).
New Biological Insights from GWAS Genes
Plasma lipids, platelets, and sickle cell disease represent three
fields in which there has been progress toward new biology
based on GWAS. GWAS for plasma LDL cholesterol, HDL
cholesterol, and triglycerides have evaluated > 100,000 partic-
ipants and have mapped 95 distinct loci associated with at
least one of these traits at a stringent statistical threshold
(p < 5 3 108) (Kathiresan et al., 2008, 2009b; Pollin et al.,
2008; Teslovich et al., 2010; Willer et al., 2008). Approximately
one-third of the loci harbored genes previously appreciated
to play a role in lipoprotein metabolism, including five targets
of lipid-modifying therapies: HMGCR (statins), NPC1L1 (ezeti-
mibe), APOB (mipomersen), CETP (anacetrapib, dalcetrapib,
and evacetrapib), and PCSK9 (therapies in development by
several pharmaceutical companies) (Figure 1).
Of note, the proportion of overall phenotypic variance ex-
plained by a genetic variant may have little correlation with theultimate therapeutic or biological value of the gene mapped
by the variant. Phenotypic variance explained by a variant is
a function of two key parameters: allele frequency and effect
size. For Mendelian diseases, the causal variants typically
confer large effects but explain a small proportion of trait vari-
ance due to their rare frequencies. Variants from GWAS are
common but explain a small proportion of trait variance due to
modest effects. Nevertheless, variants that explain a small
proportion of phenotypic variance may provide substantial bio-
logical or therapeutic insights. This has been highlighted for
Mendelian genes in Table 1. Two examples for common SNPs
include variants in the introns of HMGCR and NPC1L1 (Teslo-
vich et al., 2010). These SNPs confer a small effect on plasma
LDL cholesterol at 3 mg/dl and 2 mg/dl, respectively; however,
targeting of these genes with statins or ezetimibe, respectively,
has a much more dramatic effect on LDL cholesterol. And to
date, there have been no rare, large-effect Mendelian mutations
described in HMGCR, presumably because such mutations
are highly deleterious and not tolerated. Thus, some disease
genes may only be discoverable through common, small-effect
variants.
Approximately two-thirds of the 95 loci discovered for plasma
lipid traits harbored genes not previously appreciated to play
a role in the biology of lipoproteins. Several genes at the ‘‘novel’’
loci have now been manipulated in the mouse, and this manipu-
lation led to plasma lipid changes analogous to that suggested
by the human genetics. An example is the 8q24 locus containing
the tribbles homolog 1 (TRIB1) gene (Burkhardt et al., 2010). DNA
sequence variants downstream of the TRIB1 gene were initially
associated with plasma lipids, with the minor allele having
association with lower plasma triglycerides, lower plasma LDL
cholesterol, and higher plasma HDL cholesterol. Given this
pattern of plasma lipid changes, minor allele carriers would be
expected to have lower risk for coronary heart disease, and
several groups have confirmed this expectation (Varbo et al.,
2011). Targeted deletion of Trib1 in mice led to elevated levels
of plasma triglycerides and cholesterol, whereas liver-specific
overexpression of Trib1 reduced levels of plasma triglycerides
and cholesterol. SORT1, GALNT2, PPP1R3B, and TTC39B are
four other genes implicated in lipoprotein regulation by GWASCell 148, March 16, 2012 ª2012 Elsevier Inc. 1245
and are confirmed in a similar manner using mouse models
(Musunuru et al., 2010b; Teslovich et al., 2010).
Analogous to plasma lipids, well-powered GWAS and experi-
mental follow-up in cells and model organisms have identified
new regulators of thrombopoiesis and/or erythropoiesis. A
GWAS study for blood platelet count and volume mapped 58
loci (Gieger et al., 2011). For genes at 11 mapped loci, gene
silencing in either the zebrafish or Drosophila led to alterations
in thrombopoiesis and/or erythropoiesis. The precise mecha-
nisms by which these genes alter blood cell formation remain
to be defined through additional studies; however, we now
have a plethora of new genes for experimental follow-up, all
with a foundation of relevance to human phenotypes.
The identification of BCL11A as a transcriptional regulator of
fetal hemoglobin synthesis and as a potential therapeutic target
for sickle cell disease represents more biology learned from
GWAS. Sickle cell disease results from the substitution of a valine
for glutamic acid in the b-globin chain of adult hemoglobin. The
mutated hemoglobin (HbS) undergoes conformational change
and polymerization upon deoxygenation, leading to hemolysis,
red blood cell deformation, and pathology due to microvascular
occlusion. Hereditary persistence of fetal hemoglobin (HbF)
decreases the severity of sickle cell disease, and the level of
HbF in adults is inherited as a quantitative trait. As a result, induc-
tion of HbF in adults has been a long-standing goal of therapies
for sickle cell disease. In 2007, GWAS for the HbF phenotype
revealed a single strong locus, with sequence variants in the
intron of a transcription factor, B cell CLL/lymphoma 11A
(BCL11A) (Menzel et al., 2007). A series of elegant studies led
by Orkin and colleagues has now established that BCL11A
represses the transcription of HbF expression in erythroid cells
(Sankaran et al., 2008, 2009; Xu et al., 2010) and demonstrated
that inactivation of BCL11A in a mouse model of sickle cell
disease leads to pancellular induction of HbF and corrected
the hematologic and pathologic defects of the disease (Xu
et al., 2011).
Despite these successes, for the vast majority of mapped loci,
it has been a challenge to move from genomic localization to
biologic mechanism. Why? First, as discussed earlier in the
context of discovery of Mendelian disease genes, inferring
new biology from human genetics takes time, and only about
5 years have elapsed since the initial GWAS publications.
Second, gene mapping and experimental follow-up require
unique skill sets and expertise. In the examples highlighted
above, collaborations between experimentalists and re-
searchers focused on human genetics have been crucial to
making progress, yet skepticism regarding the validity and value
of discoveries made from GWAS may have dampened the
enthusiasm for such collaborations (McClellan and King, 2010).
Third, genetic mapping by association gives us gene regions
and not necessarily specific causal variants or causal genes.
For each SNP and locus mapped by GWAS, we can generally
conclude that, within 100,000 bases of the locus, there
exists a causal gene. Ideally, at each discovered locus, we
need to understand: (1) the causal variant, (2) the causal gene,
(3) the mechanism by which the variant affects the gene, and
(4) the mechanism by which the gene affects the phenotype.
At the 1p13 locus for LDL cholesterol and MI, fine-mapping,1246 Cell 148, March 16, 2012 ª2012 Elsevier Inc.resequencing, and manipulation of positional candidate genes
in cell culture and model organisms have addressed these key
questions (Musunuru et al., 2010b). However, at most loci, the
answers remain a mystery.
Several features of genetic mapping using common variants
have contributed to the difficulties. Local correlation (linkage
disequilibrium) and weak effect size of common variants have
made it difficult to identify causal variants. Mapped SNP variants
have weak or modest effect (odds ratios of 1.05 to 1.40 for
a dichotomous trait and < 1% of variance explained for contin-
uous traits), and these weak effects mean that, in order to statis-
tically distinguish between two correlated variants, the sample
sizes need to be inordinately large. Nearly all of the mapped
SNP variants are noncoding, and our ability to interpret the non-
coding portion of the genome remains limited. Mechanisms by
which a noncoding variant may affect a nearby gene include,
among others, affecting a transcription factor or microRNA-
binding site and regulating the local chromatin state.
In only a few instances has there been direct demonstration
that a specific noncoding GWAS SNP affects the relevant gene
through one of these mechanisms (Musunuru et al., 2010b).
The example of chromosome 9p21 and risk for MI exemplifies
the challenge. In 2007, several independent GWASs identified
SNPs on chromosome 9p21 as associated with MI or coronary
artery disease, with50% of the population carrying a risk allele
and each copy of the risk allele conferring 29% increase in
risk for MI/coronary artery disease (Helgadottir et al., 2007;
McPherson et al., 2007; Samani et al., 2007). The most strongly
associated SNPs were noncoding and > 100 kilobases down-
stream of the nearest protein-coding genes CDKN2B (cyclin-
dependent kinase inhibitor 2B encoding the protein p15INK4b)
and CDKN2A (cyclin-dependent kinase inhibitor 2A encoding
the proteins p16INK4a and p14ARF). Resequencing and fine-
mapping studies in the gene region have identified a set of
SNPs with indistinguishable statistical evidence, but not one
causal variant (Shea et al., 2011). By what mechanism does
the risk allele alter the relevant gene at the locus, and what is
the gene that is responsible for atherosclerosis susceptibility?
Answers to these two questions have been particularly elusive.
Several mechanisms by which the noncoding variant might
impact phenotype have been explored, including alteration of
a noncoding RNA in the region (e.g., antisense noncoding RNA
in the INK4 locus [ANRIL]) and disruption of the binding of a
transcription factor, as observed with STAT1 (Harismendy
et al., 2011; Holdt and Teupser, 2012). No definitive answers
have emerged. Finally, a noncoding gene region homologous
to the human-associated interval on 9p21 was deleted in mice,
and this targeted deletion led to near absence of CDKN2A and
CDKN2B expression in several tissues, increased rate of tumors,
and increased proliferation of aortic smooth muscle cells (Visel
et al., 2010). However, these mice did not develop increased
atherosclerosis on a diet rich in fat and cholesterol. For the
9p21 locus, the path from genomic localization to functional
insights has not been straightforward, likely due to our limited
ability at present to interpret the noncoding portions of the
human genome. However, as recently reviewed (Raychaudhuri,
2011), integration of GWAS findings with expression quantitative
trait loci (eQTL) (eQTLs are genetic variants that correlate with
the transcript level of a gene) and genome-wide maps of
chromatin state dynamics may improve our ability to interpret
GWAS findings and understand how noncoding variation regu-
lates genes (Ernst et al., 2011; Schadt et al., 2008).
Gene Variants May Distinguish Causal
from Noncausal Biomarkers
Hypotheses concerning etiologic agents for complex diseases
have often initially come from observational epidemiology. In
1961, in a paper entitled ‘‘Factors of Risk in the Development
of Coronary Heart Disease,’’ Dr. William Kannel and colleagues
at the Framingham Heart Study established an association of
plasma total cholesterol with future risk for coronary heart
disease (Kannel et al., 1961). Since then, hundreds of soluble
biomarkers have similarly been associated with risk for coronary
artery disease. How many of these biomarkers directly cause
coronary artery disease, and how many simply reflect other
causal processes? And why is this question important? Both
causal and noncausal biomarkers may be helpful in terms of
predicting risk for future disease. However, only a causal
biomarker may be appropriate as a target of therapy. The ulti-
mate proof of causality in humans is a randomized controlled trial
testing whether a treatment that alters the biomarker will affect
disease risk. However, as clinical trials are expensive and time-
consuming, it would be helpful to have evidence in humans prior
to engaging in a clinical trial.
In a technique termedMendelian randomization, DNA variants
are used to address the question of whether an epidemiological
association between a risk factor and disease reflects a causal
influence of the former on the latter (Davey Smith and Ebrahim,
2003; Gray and Wheatley, 1991; Katan, 1986). In principle, if
a DNA variant is known to directly affect an intermediate pheno-
type (e.g., a variant in the promoter of a gene encoding a
biomarker, affecting its expression) and the intermediate pheno-
type truly contributes to the disease, then the DNA variant
should be associated with the disease to the extent predicted
by: (1) the size of the effect of the variant on the phenotype
and (2) the size of the effect of the phenotype on the disease
(Musunuru and Kathiresan, 2010). If in an adequately powered
sample, the predicted association between the variant and
disease was not observed, it would argue against a purely causal
role for the intermediate phenotype in the pathogenesis of the
disease. The study design is akin to a prospective randomized
clinical trial in that the randomization for each individual occurs
at the moment of conception—genotypes of DNA variants are
randomly ‘‘assigned’’ to gametes during meiosis, a process
that should be impervious to the typical confounders observed
in observational epidemiological studies. For example, a parent’s
disease status or socioeconomic status should not affect which
of the parent’s two alleles at a given SNP is passed to a child,
with each allele having an equal (50%) chance of being trans-
mitted via the gamete to the zygote. Thus,Mendelian randomiza-
tion should be unaffected by confounding or reverse causation.
Mendelian randomization has potential shortcomings, including:
(1) the technique is only as reliable as the robustness of the
estimates of the effect sizes of the variant on the phenotype
and of the phenotype on disease and (2) it assumes that the
DNA variant does not influence the disease by means other
than the intermediate phenotype being studied (pleiotropy),which may not be true. Nevertheless, Mendelian randomization
has the potential to be as informative as a traditional randomized
clinical trial.
Several Mendelian randomization studies have confirmed
a causal relationship between LDL cholesterol and coronary
artery disease. Nonsense variants in the PCSK9 gene that signif-
icantly reduce plasma LDL cholesterol concentrations were
observed to be associated with reduced incidence of coronary
artery disease in an African American cohort (Cohen et al.,
2006). Similarly, in European Americans, a common missense
variant in PCSK9 associated with lower LDL cholesterol levels
was also found to be associated with lower risk of MI. These
observations suggested that lower LDL cholesterol is sufficient
to provide protection against coronary artery disease. Similar
to LDL cholesterol, several recent genetic studies have con-
firmed prior observations that plasma lipoprotein(a) causally
relates to coronary artery disease (Clarke et al., 2009; Kamstrup
et al., 2009).
Unlike the results with plasma LDL cholesterol concentrations
and plasma lipoprotein(a), three recent, large Mendelian
randomization studies of C-reactive protein gene (CRP) variants
that affect plasma CRP concentrations, performed in thousands
of individuals, did not show an association between these vari-
ants and ischemic vascular disease or coronary artery disease
(Elliott et al., 2009; Wensley et al., 2011; Zacho et al., 2008). It
is unlikely that these studies were confounded or affected by
pleiotropy, as the tested variants were within the CRP gene itself
rather than being in other loci that might secondarily affect
CRP levels. Although these studies cannot definitively rule out
a causal role of CRP in cardiovascular disease, they strongly
suggest that high CRP levels are indirectly rather than directly
related to coronary artery disease.
A parallel line of genetic evidence also casts doubt on the
notion that inflammatory biomarkers such as CRP are critical
mediators of MI and coronary artery disease. Of 33 loci most
highly associated with MI and coronary artery disease (Table 2),
nine are related to plasma LDL cholesterol or lipoprotein(a),
arguing for a strong causal relationship between LDL (or a modi-
fied LDL particle such as lipoprotein(a)) and disease (Schunkert
et al., 2011). None of the other 24 loci are clearly related to
inflammation. Overall, with the recent explosion in our ability to
measure both soluble biomarkers (including metabolites and
proteins) and genetic variation, Mendelian randomization will
likely be an increasingly utilized approach to distinguish causal
biomarkers from noncausal ones.
Next Generation of Approaches
Massively Parallel Sequencing as a Discovery Tool
As described above, considerable progress has been made in
correlating genotype to phenotype for both Mendelian and
common, complex diseases over the past several decades.
Over the next decade, we are in a unique position to ‘‘finish the
job.’’ For Mendelian diseases, the goal is nothing short of
attempting to solve all Mendelian diseases not yet mapped.
For common, complex diseases, the goal is to extend the range
of genetic variation evaluated from common (>1:20 frequency)
to low-frequency (1:1,000–1:20 frequency) and very rare
(<1:1,000 frequency).Cell 148, March 16, 2012 ª2012 Elsevier Inc. 1247
Table 2. Genetic Loci Mapped by GWAS for Myocardial Infarction or Coronary Artery Disease
Unique
Locus Chr SNP
Risk Allele
Frequency
Odds Ratio
(95% CI) per
Risk Allele
Genes of Interest
within or Near
Associated
Interval
Association of SNP
or Proxy with Other
Cardiovascular
Phenotypes References
Also associated with established risk factor—plasma LDL cholesterol
1 1p13 rs599839 78% 1.11 (1.08–1.15) CELSR2, PSRC1,
SORT1
eQTL for SORT1, CELSR2,
and PSRC1 transcript
levels in liver
(Samani et al., 2007;
Schunkert et al., 2011)
2 19p13 rs6511720 89% 1.18 (1.11–1.25) LDLR (IBC 50K CAD
Consortium, 2011;
Kathiresan et al., 2009a)
3 1p32 rs11206510 82% 1.08 (1.05–1.11) PCSK9 (Kathiresan et al., 2009a)
4 6q25 rs3798220 2% 1.51 (1.33–1.70) LPA lipoprotein(a) (Clarke et al., 2009)
4 6q26 rs10455872 7% 1.68 (1.43–1.98) LPA lipoprotein(a) (Clarke et al., 2009)
5 9q34 rs579459 21% 1.10 (1.07–1.13) ABO venous thromboembolism,
ACE enzyme activity,
plasma E-selectin level,
plasma vWF level,
among others
(Reilly et al., 2011;
Schunkert et al., 2011)
6 11q23 rs964184 13% 1.13 (1.10–1.16) ZNF259, APOA5,
APOA1
triglycerides,
HDL cholesterol
(Schunkert et al., 2011)
7 8q24 rs17321515 53% 1.06 (1.03–1.10) TRIB1 triglycerides,
HDL cholesterol
(IBC 50K CAD Consortium,
2011; Varbo et al., 2011)
8 2p21 rs4299376 32% 1.07 (1.04–1.11) ABCG5, ABCG8 serum phytosterols (IBC 50K CAD Consortium,
2011; Teupser et al., 2010)
9 19q13 rs2075650 14% 1.14 (1.09–1.19) APOE (IBC 50K CAD
Consortium, 2011)
Also associated with established risk factor—blood pressure
10 12q24 rs3184504 44% 1.07 (1.04–1.10) SH2B3 LDL cholesterol, platelet
count, plasma eosinophil
count, among others
(Gudbjartsson et al., 2009;
Schunkert et al., 2011)
11 10q24 rs12413409 89% 1.12 (1.08–1.16) CYP17A1,
CNNM2, NT5C2
intracranial aneurysm (Schunkert et al., 2011;
Yasuno et al., 2010)
Unknown mechanism by which variant confers risk for myocardial infarction or coronary artery disease
12 9p21 rs4977574 46% 1.29 (1.23–1.36) CDKN2A,
CDKN2B, ANRIL
coronary artery calcification,
intracranial aneurysm,
abdominal aortic
aneurysm, among others
(Wellcome Trust Case
Control Consortium, 2007;
Helgadottir et al., 2007;
McPherson et al., 2007)
13 21q22 rs9982601 15% 1.18 (1.12–1.24) SLC5A3, MRPS6,
KCNE2
eQTL for MRPS6
transcript level in blood
(Kathiresan et al., 2009a)
14 1q41 rs17465637 74% 1.14 (1.09–1.20) MIA3 (Samani et al., 2007)
15 10q11 rs1746048 87% 1.09 (1.07–1.13) CXCL12 plasma CXCL12 level (Samani et al., 2007)
16 6p24 rs12526453 67% 1.10 (1.06–1.13) PHACTR1 coronary artery calcification (Kathiresan et al., 2009a)
17 2q33 rs6725887 15% 1.14 (1.09–1.19) WDR12, NBEAL1 eQTL for NBEAL1 transcript
level in aortic media
(Kathiresan et al., 2009a)
18 3q22 rs9818870 18% 1.12 (1.07–1.16) MRAS eQTL for MRAS transcript
level in aortic media
(Erdmann et al., 2009)
19 1p32 rs17114036 91% 1.17 (1.13–1.22) PPAP2B (Schunkert et al., 2011)
20 6p21 rs17609940 75% 1.07 (1.05–1.10) ANKS1A (Schunkert et al., 2011)
21 6q23 rs12190287 62% 1.08 (1.06–1.10) TCF21 eQTL for TCF21 transcript
level in liver, fat
(Schunkert et al., 2011)
22 7q32 rs11556924 62% 1.09 (1.07–1.12) ZC3HC1 (Schunkert et al., 2011)
23 13q34 rs4773144 44% 1.07 (1.05–1.09) COL4A1, COL4A2 (Schunkert et al., 2011)
24 14q32 rs2895811 43% 1.07 (1.05–1.10) HHIPL1 (Schunkert et al., 2011)
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Table 2. Continued
Unique
Locus Chr SNP
Risk Allele
Frequency
Odds Ratio
(95% CI) per
Risk Allele
Genes of Interest
within or Near
Associated
Interval
Association of SNP
or Proxy with Other
Cardiovascular
Phenotypes References
25 15q25 rs3825807 57% 1.08 (1.06–1.10) ADAMTS7 (Reilly et al., 2011;
Schunkert et al., 2011)
26 17p13 rs216172 37% 1.07 (1.05–1.09) SMG6 (Schunkert et al., 2011)
27 17p11 rs12936587 56% 1.07 (1.05–1.09) RASD1, PEMT,
RAI1
eQTL for RASD1 and
PEMT transcript levels
in monocytes
(Schunkert et al., 2011)
28 17q21 rs46522 53% 1.06 (1.04–1.08) UBE2Z eQTL for UBE2Z transcript
level in blood
(Schunkert et al., 2011)
29 7q22 rs10953541 80% 1.08 (1.05–1.11) BCAP29, DUS4L (C4D, 2011)
30 10p11 rs2505083 38% 1.07 (1.04–1.09) KIAA1462 (C4D, 2011)
31 11q22 rs974819 32% 1.07 (1.04–1.09) PDGFD eQTL for PDGFD transcript
level in aortic media
(C4D, 2011)
32 10q23 rs1412444 42% 1.09 (1.07–1.12) LIPA eQTL for LIPA transcript
level in monocytes
(C4D, 2011;
Wild et al., 2011)
33 6p24 rs6903956 7% 1.65 (1.44–1.90) c6orf105 (Wang et al., 2011)Dramatic advances in sequencing and genotyping make such
ambitious goals feasible. Next-generation sequencing platforms
have markedly decreased the cost of DNA sequencing when
compared with Sanger sequencing. Hybridization approaches
have enabled selection of the portion of the genome that is
protein coding (roughly 1%of the 3.2 billion bases), the so-called
‘‘exome.’’ Sequencing just the exome (rather than the entire
genome) is well justified in the search for genetic causes of
rare inherited disorders (Ng et al., 2010). This is because the
majority of alleles that are responsible for Mendelian disorders
disrupt protein-coding sequence, and a large fraction of rare
missense mutations in the human genome are predicted to be
deleterious (Kryukov et al., 2007; Stenson et al., 2009).
Next-Generation Sequencing and Mendelian Disease
Over the past three years, whole-exome and whole-genome
sequencing have been successfully utilized to identify new
genes for several Mendelian forms of CVD. Most studies have
sequenced the exomes of one or a few individuals affected
with the disorder. Variants seen in these individuals are typically
compared with those from reference individuals (unaffected
individuals who are family members or unrelated). Variants that
are shared by affected individuals and are not present in the
unaffected population are considered causal candidates. With
this strategy, investigators identified ANGPTL3 mutations as
a cause of familial combined hypolipidemia, BAG mutations for
dilated cardiomyopathy, NT5E mutations for arterial calcifica-
tion, KCNJ5 mutations for hereditary hypertension due to aldo-
sterone-producing adenomas, and KLHL3 or CUL3 mutations
for hypertension and hyperkalemia (Boyden et al., 2012; Choi
et al., 2011; Musunuru et al., 2010a; Norton et al., 2011; St Hilaire
et al., 2011).
The discovery ofKLHL3 as a cause of pseudohypoaldosteron-
ism type II, a Mendelian form of hypertension, is an elegant
example of the value of exome sequencing (Boyden et al.,
2012). The gene was identified by directly sequencing theexomes of 11 unrelated index cases with pseudohypoaldoster-
onism type II and contrasting with exome sequences from 699
population-based, unrelated controls without hypertension.
Of 22 case chromosomes, 5 harbored a rare, protein-altering
mutation in KLHL3, whereas only 2 of 1,398 control chromo-
somes did so, leading to a low probability that this observation
was due to chance (p = 1 3 108). Such successes have raised
expectations for the exome sequencing approach.
However, the true yield of exome sequencing in solving
Mendelian disorders is difficult to know at present, as negative
results have not been routinely reported (Bamshad et al.,
2011). It can be difficult to arrive at a single causal mutation after
exome sequencing due to the following reasons. First, the causal
variant may not be protein coding. Second, the causal variant
may be protein coding, but the relevant gene may not be
successfully captured and sequenced. Approximately 5%–
10% of all exons may be poorly sequenced due to genomic
features such as high GC content. Third, if the causal mutation
is not fully penetrant, it will be present in individuals who are
both phenotypically affected and unaffected and thus may be
‘‘filtered’’ out. Fourth, the segregation of a phenotype in a family
may be due to nongenetic factors rather than a single gene of
large effect. This problem is particularly true for CVD conditions
that are common in the population like MI and atrial fibrillation.
If one observes a multigeneration family in which multiple indi-
viduals are affected with MI, is this pattern due to a new Mende-
lian gene or poor lifestyle habits shared by the family? Fifth, in
contrast to single-nucleotide substitutions, methods for calling
small insertion-deletions and copy number changes from
short-read sequence data are in need of improvement. If the
causal mutation is a one or two base-pair insertion or deletion,
it might be overlooked. Finally, exome sequencing and filtering
are more efficient at reducing the number of candidate causal
mutations for recessive rather than dominant disorders. After
exome sequencing and filtering for a dominantly inheritedCell 148, March 16, 2012 ª2012 Elsevier Inc. 1249
Figure 2. Association Signals Arising from Rare Variants
(A and B) Each line represents DNA sequence from a different individual,
and each circle represents a DNA sequence variant. Each color denotes a
DNA sequence variant allele at a different nucleotide site.
(A) ‘‘Low-frequency’’ variants can be defined as variants in frequency between
1:1000 and 1:20. Each variant can be assayed typically by genotyping and
tested for association individually using single marker tests of association.
(B) ‘‘Very Rare’’ variants can be defined as variants with frequency less than
1:1,000, and often the variant may be seen only in a single person (i.e.,
a singleton). Variants in this frequency range need to be grouped together and
tested in aggregate. Association signals from a burden of such very rare
variants are typically best validated using resequencing of the same genomic
interval in additional individuals. Figure adapted from Manolio et al. (2009).condition, the number of mutations compatible with causing
disease can be large.
Next-Generation Sequencing and Common,
Complex Disease
What about exome or whole-genome sequencing to identify rare
variants that confer a large effect on common, complex traits and
diseases? The optimal study design for complex traits will
depend on the frequency of the genetic variant(s) that are the
source of the association signal. Though the term ‘‘rare’’ is
used in the literature to refer to variants less than 1:20 frequency,
we find it useful to distinguish between two types of ‘‘rare’’ vari-
ants, those that range in frequency from 1:1,000 to 1:20 and
are denoted as ‘‘low-frequency’’ and those that are < 1:1,000
frequency and are denoted as ‘‘very rare’’ (Figure 2). This cate-
gorical distinction is important because the approach to discover
and replicate the two signals can differ.
For low-frequency variants, it is now possible to catalog
nearly all coding variants segregating in a population at a
frequency of 1:1,000 or greater, directly genotype these vari-
ants, and test for association with disease (Figure 2A). For
example, data from 12,000 human exome sequences have
been mined, and all coding sites where the alternate allele
is seen at least three times (twice for nonsense and splice)
and in two separate studies have been cataloged. Investigators
have designed a custom genotyping array—the ‘‘Exome
Chip’’ —to directly genotype these 300,000 variants at low
cost. This genotyping array will allow for comprehensive
testing of low-frequency coding variants for association with
cardiovascular traits and diseases.1250 Cell 148, March 16, 2012 ª2012 Elsevier Inc.In contrast, a signal emerging from a burden of very rare vari-
ants can best be discovered by sequencing and can often only
be replicated by sequencing (Figure 2B). The promise and
challenges of this approach are evident in the candidate gene
sequencing studies completed over the past few years. In
seminal work, Cohen, Hobbs, and colleagues tested the hypoth-
esis that rare, coding variation in candidate genes contributes to
plasma HDL cholesterol variation in the population (Cohen et al.,
2004). Three genes that cause Mendelian forms of low HDL
cholesterol (ABCA1, APOA1, and LCAT) were sequenced in
128 individuals ascertained from the lowest 5th percentile
(mean, 31 mg/dl) and in 128 individuals from the highest 95th
percentile of the HDL cholesterol distribution (mean, 91 mg/dl)
in a population-based cohort study. The investigators aggre-
gated rare variants that met three criteria: (1) present within a
gene, (2) changed amino acid, and (3) exclusively present in
either the low or high group. Twenty such rare alleles were found
in the low group, and two such rare alleles were found in the
high group (Fisher’s exact, p = 0.00006). This observation was
replicated in an independent study, and additionally, cells from
mutation carriers had reduced cholesterol efflux rates, a key
function of ABCA1. This study established that rare nonsynony-
mous mutations in ABCA1 with large phenotypic effects
contribute to low HDL cholesterol in the population.
The challenge now is to utilize sequencing to enable de
novo discovery of new genes that contribute to complex traits.
It has become practical to extend the experiment described
above from the sequencing of three genes to 20,000 genes.
Exomes can be rapidly sequenced, and single-nucleotide
substitutions can be accurately called; however, will such
sequencing for complex traits readily yield new discoveries?
The key barriers at present are statistical. DNA sequence vari-
ants that are very rare (e.g., a mutation seen in a single person
or a singleton) cannot be tested individually for association
with phenotype. Instead, they need to be aggregated with
similar rare variants to be tested collectively for association
with phenotype (Figure 2B).
This requirement immediately brings forward several ques-
tions. Do we only aggregate variants within a single gene, or
should it be extended to collections of genes in a pathway? Do
we only group variants of a certain annotation—nonsynony-
mous, nonsense, synonymous, splice site, etc.? Should we
impose a frequency threshold to define ‘‘rare’’ (i.e., only aggre-
gate variants that are less than 1% frequency), and if so, what
should this frequency threshold be? The answers to many of
these questions are in development. We refer the reader to
several recent publications that address these issues (Li and
Leal, 2008; Madsen and Browning, 2009; Neale et al., 2011;
Price et al., 2010).
Another key question is statistical power. What sample size
will be required to identify a newdisease gene based on a burden
of rare coding mutations? An early computer simulation study
conducted by Kryukov, Sunyaev, and colleagues suggested
that 10,000 individuals (5,000 drawn from the lowest 5th percen-
tile and 5,000 above the 95th percentile) will be needed to
discover another gene with a mutation burden similar to
ABCA1 (Kryukov et al., 2009). The principal reason for this large
sample size is the stringent statistical threshold that needs to be
Figure 3. Estimate of Sample Sizes Required for Gene Discovery in Exome Sequencing Studies of Complex Traits
Extrapolations were performed using gene resequencing counts from published candidate gene studies. Fisher’s exact test was performed for gene burden
testing on mutation carrier status within each study. The red horizontal line indicates the genome-wide p value threshold (p = 2.53 106) for gene burden of rare
variants with minor allele frequencies < 1%. The extrapolations show that thousands of samples are needed to exceed statistical significance at a genome-wide
level. Rare variant counts for ANGPTL3, ANGPTL4, and ANGPTL5 for plasma triglycerides were obtained from Romeo and colleagues (Romeo et al., 2009);
APOA5, APOB, GCKR, and LPL for hypertriglyceridemia from Johansen and colleagues (Johansen et al., 2010); SLC12A3/SLC12A1/KCNJ1 from Ji and
colleagues (Ji et al., 2008).imposed when testing 20,000 genes. A first approximation of the
appropriate statistical threshold would be Bonferroni correction
for all of the genes sequenced (p = 2.53 106). Our extrapolation
of effect sizes and frequencies from published studies shows
(Figure 3) that thousands of individuals are required to reach
acceptable statistical power.
Statistical power would improve dramatically if we were
able to distinguish rare mutations that affected protein function
from those that did not. The bulk of discovered rare mutations
are missense. Of all missense, it is estimated that 1/5 are as
deleterious as nonsense mutations, 1/2 are mildly deleterious,
and 1/4 do not affect protein function (Kryukov et al., 2007).
If one restricted mutation counts to only functional mutations,
noise would be removed (MacArthur et al., 2012). At present,
functional consequence of variants can be predicted based on
comparative sequence analysis and protein structure analysis.
Several software tools are available, and the accuracy of these
methods remains a subject of debate (Sunyaev et al., 2001).
An alternative method is experimental evaluation of whether
a given mutation is functional. Such experimental evaluation is
possible for genes with known function and where that function
can be readily evaluated with moderate- or high-throughput
approaches. However, such evaluation of mutations assumes
that the parameter evaluated is an appropriate surrogate for themechanism by which the gene impacts the human phenotype.
For complex phenotypes such as MI that arise after decades of
pathology, it is often difficult to know whether this is the case.
Nevertheless, distinguishing functional versus neutral missense
mutations will be a key to improving statistical power.
Modeling Human Genetic Disease in Reprogrammed
Cells
As an increasing number of genetic variants become associated
with human disease, it will be essential to develop effective
and accurate model systems to understand the mechanism of
disease. This step is a prerequisite to translate genetic findings
into new targets for therapy. Animal models have traditionally
been used to mimic human mutations through gene knockin
approaches or study of null mutations (Bruneau et al., 2001;
Lindsay et al., 2001). Though this approach has been of value
and has led to many discoveries, it is more common that mouse
models fail to effectively recapitulate the human phenotype. This
situation is even true for Mendelian traits, wherein heterozygous
deletion of human disease genes is often well tolerated in
mice, whereas homozygous deletions can have catastrophic
consequences, failing to model the human condition. For many
human disease genes, this has been a bottleneck, limiting the
value of gene-hunting approaches described above.Cell 148, March 16, 2012 ª2012 Elsevier Inc. 1251
Figure 4. Modeling Human Genetic Disease in Reprogrammed Cells
Reprogrammed cells derived from skin fibroblasts or blood cells of individuals
with genetic variants associated with disease can be used for disease
modeling and drug discovery and to determine the impact of sequence vari-
ants on cellular biology. Reprogramming to induced pluripotent stem (iPS)
cells and subsequent directed differentiation to relevant cell types can yield
large numbers of human disease-related cell types for investigation. Specific
genetic variants can also be engineered into human pluripotent stem cells
using zinc-finger nucleases or TALENs to generate iPS or embryonic stem (ES)
cells harboring disease-associated variants. Future approaches involving
transdifferentiation may allow for a more direct approach to generate relevant
cell types for study of CVD. In some cases, diseases will be cell autonomous,
but other cases may require coculture of two or more cell types to recapitulate
the disease process.The recent revolution in cellular reprogramming technology
provides a potential solution to the need for disease modeling
(Figure 4). The striking observation by Yamanaka and colleagues
that human adult somatic cells could be reprogrammed into
a pluripotent state by expressing four transcription factors not
only revolutionized the field of stem cell biology, but also has
major consequences for the study of human genetics (Takahashi
et al., 2007). Investigators can now reprogram skin or blood cells1252 Cell 148, March 16, 2012 ª2012 Elsevier Inc.from patients with defined genetic variants/mutations into
induced pluripotent stem (iPS) cells and can then differentiate
the iPS cells into the specific cell type affected by disease.
This approach provides an unprecedented opportunity to inves-
tigate the consequences of human genetic variation on cellular
phenotypes that may contribute to disease. There have been
several reports of partial modeling of CVD using human iPS cells
in the last 2 years, although success to date has been limited to
diseases with discrete cell-autonomous cellular defects. We will
consider a few examples below and highlight the advantages
and limitations of this approach.
Autosomal-dominant long QT syndrome (LQTS) that predis-
poses to cardiac arrhythmias and sudden death involves
single-gene mutations of sodium or potassium channels that
provide a discrete and quantitative phenotype in iPS-derived
cardiomyocytes. In LQTS, repolarization of cardiomyocytes is
delayed, resulting in a prolonged action potential duration.
Several groups have reported successful generation of iPS-
derived cardiomyocytes from patients with LQTS, and an elon-
gation of the action potential duration has been reported for
a subset of genetically induced LQTS (Itzhaki et al., 2011; Moretti
et al., 2010; Yazawa et al., 2011). LQTS can also be drug induced
in selected individuals, and pluripotent stem cell-derived cardio-
myocytes appear to be an effective model system to detect
prolongation of action potentials due to cardiotoxic drugs
(Braam et al., 2010). It is exciting to consider that identification
of common genetic variants that predispose to drug-induced
LQTSmight bemodeled in iPS-derived cardiomyocytes, thereby
allowing a system in which to screen for this toxic side effect
prior to in vivo use of new drugs.
Despite these successes, certain types of LQTS have been
more difficult to model due to the incomplete maturation of
iPS-derived cardiomyocytes and appropriate expression of ion
channels in a consistent manner. It is possible that recent direct
reprogramming strategies involving transdifferentiation, which
do not involve a progenitor intermediate, will allow modeling of
diseases in which a mature cell type is required (Ieda et al.,
2010). The inability to expand mature, transdifferentiated cells
is currently a rate-limiting factor for this approach, but future
improvements in efficiency of reprogramming may overcome
this hurdle.
Another example of iPS-based modeling recently came from
the study of Noonan and LEOPARD syndromes, autosomal-
dominant conditions that involve pulmonary valve stenosis and
hypertrophic cardiomyopathy in a subset of patients (Gelb and
Tartaglia, 2011). The genetic cause of Noonan and LEOPARD
syndromes involves activating mutations in members of the
Ras pathway. Correspondingly, iPS-derived cardiomyocytes
from patients with cardiomyopathy associated with LEOPARD
syndrome exhibit higher levels of Ras signaling that appear to
contribute to excessive growth of cardiac cells (Carvajal-Vergara
et al., 2010). Though such findings successfully model the
pathway known to be affected, the ultimate goal will be to
identify new therapeutics that can disrupt abnormal pathways
and restore normal physiology. This has remained elusive thus
far, in part because most iPS-based disease models lead
to broad variability in phenotype, whereas high-throughput
screening assays typically require a consistent phenotype with
a narrow range of variability. As protocols for generating iPS
cells improve and directed differentiation methods become
more consistent, ‘‘disease in a dish’’ models promise to alter
the landscape of drug discovery (Figure 4).
Besides modeling the Mendelian syndromes described
above, another potential use of iPS technology will be to anno-
tate the function of SNPs identified by GWAS or rare mutations
discovered by sequencing. iPS cells are currently being gener-
ated from large populations with defined genetic variants and
CVD in the hope that certain aspects of the phenotype could
be modeled in iPS-derived cells. It may prove difficult to identify
consistent phenotypic differences associated with genetic
variants of small effect; however, it is possible that the genetic
background present in affected individuals will be sufficient to
reveal a cellular defect.
The contribution of individual sequence variants in the
context of complex genetic background issues can be interro-
gated through the use of recently developed DNA correction
approaches in human pluripotent stem cells. The use of zinc-
finger nucleases and transcription activator-like effector
nuclease (TALEN) technology to specifically introduce or re-
move a sequence variant in stem cells will reveal the contribu-
tion of individual variants to cellular phenotypes (Yusa et al.,
2011). Addition of environmental stresses to the cellular system
may be necessary to provoke phenotypes and will be an impor-
tant tool in disease modeling in iPS cells. Such studies are
currently underway, and we look forward to the challenges
and opportunities offered by this new approach to modeling
human genetic variants.
Conclusions
The tools to decode human genetic variants on a large popula-
tion scale have finally arrived and should begin to reveal the
genetic contribution to disease at an exponential pace. Rigorous
analysis of the functional consequences of sequence variants
associated with disease will be critical, and new approaches
leveraging stem cell technologies may facilitate study of human
variants in relevant human cell types. Ultimately, the conver-
gence of human genetics with functional biology will reveal
new therapeutic targets for cardiovascular disease and will
stimulate a new generation of drug discovery efforts.
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